Feasibility, safety and efficacy of concomitant curcumin in patients undergoing palliative radiotherapy for FIGO stage IIIB–IVA cervical cancer: An open-label pilot trial

dc.contributor.author	Ethiopian Food and Drug Authority
dc.date.accessioned	2026-02-24T06:59:32Z
dc.date.available	2026-02-24T06:59:32Z
dc.date.issued	2024
dc.identifier.uri	http://repository.iphce.org/xmlui/handle/123456789/5326
dc.description.abstract	The rationale for combining curcumin with radiotherapy in the context of treating stage IIIB-IVA cervical cancer aims to enhance therapeutic efficacy while mitigating treatment related toxicities. Envisaged synergies between curcumin and radiotherapy, coupled with the potential reduction in radiation-induced toxicities, offer a promising pathway to advance treatment strategies and enhance patient care standards in these challenging clinical situations. To enhance the bioavailability, novel curcumin formulation, CurQfenTM or curcumagalactomannoside (CGM), is used.	en_US
dc.language.iso	en_US	en_US
dc.subject	Cervical cancer	en_US
dc.title	Feasibility, safety and efficacy of concomitant curcumin in patients undergoing palliative radiotherapy for FIGO stage IIIB–IVA cervical cancer: An open-label pilot trial	en_US
dc.type	Report	en_US